HK1231473A1 - 作為毒蕈碱 和/或 受體激動劑的雙環氮雜化合物 - Google Patents

作為毒蕈碱 和/或 受體激動劑的雙環氮雜化合物

Info

Publication number
HK1231473A1
HK1231473A1 HK17105049.1A HK17105049A HK1231473A1 HK 1231473 A1 HK1231473 A1 HK 1231473A1 HK 17105049 A HK17105049 A HK 17105049A HK 1231473 A1 HK1231473 A1 HK 1231473A1
Authority
HK
Hong Kong
Prior art keywords
receptor
muscarinic
aza compounds
bicyclic aza
agonists
Prior art date
Application number
HK17105049.1A
Other languages
English (en)
Chinese (zh)
Inventor
Giles Albert Brown
Julie Elaine Cansfield
Miles Stuart Congreve
Michael Alistair OBRIEN
Mark Pickworth
Mark David Rackham
Benjamin Gerald Tehan
Barry John Teobald
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1402013.5A external-priority patent/GB201402013D0/en
Priority claimed from GBGB1416622.7A external-priority patent/GB201416622D0/en
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of HK1231473A1 publication Critical patent/HK1231473A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
HK17105049.1A 2014-02-06 2017-05-19 作為毒蕈碱 和/或 受體激動劑的雙環氮雜化合物 HK1231473A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1402013.5A GB201402013D0 (en) 2014-02-06 2014-02-06 Pharmaceutical compounds
GBGB1416622.7A GB201416622D0 (en) 2014-09-19 2014-09-19 Pharmaceutical compounds
PCT/GB2015/050331 WO2015118342A1 (fr) 2014-02-06 2015-02-06 Composés aza bicycliques en tant qu'agonistes du récepteur muscarinique m1.

Publications (1)

Publication Number Publication Date
HK1231473A1 true HK1231473A1 (zh) 2017-12-22

Family

ID=52465550

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105049.1A HK1231473A1 (zh) 2014-02-06 2017-05-19 作為毒蕈碱 和/或 受體激動劑的雙環氮雜化合物

Country Status (28)

Country Link
US (6) US9670183B2 (fr)
EP (2) EP3406609A1 (fr)
JP (6) JP6479029B2 (fr)
KR (1) KR102352388B1 (fr)
CN (2) CN109851610B (fr)
AU (3) AU2015213900B2 (fr)
BR (1) BR112016017979B1 (fr)
CA (1) CA2938169C (fr)
CL (1) CL2016001983A1 (fr)
CY (1) CY1120834T1 (fr)
DK (1) DK3102568T3 (fr)
ES (1) ES2688548T3 (fr)
HK (1) HK1231473A1 (fr)
HR (1) HRP20181499T1 (fr)
IL (1) IL247117B (fr)
LT (1) LT3102568T (fr)
MX (2) MX371529B (fr)
NZ (1) NZ723103A (fr)
PH (1) PH12016501570B1 (fr)
PL (1) PL3102568T3 (fr)
PT (1) PT3102568T (fr)
RS (1) RS57843B1 (fr)
RU (1) RU2685230C2 (fr)
SA (1) SA516371614B1 (fr)
SG (1) SG11201606269WA (fr)
SI (1) SI3102568T1 (fr)
UA (1) UA122121C2 (fr)
WO (1) WO2015118342A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187451B2 (en) 2011-11-18 2015-11-17 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
DK2968297T3 (en) 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
CA2938169C (fr) 2014-02-06 2022-03-15 Heptares Therapeutics Limited Composes d'aza bicyclique comme agonistes de recepteur muscarinique m1
GB201404922D0 (en) * 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
KR20170048410A (ko) 2014-09-17 2017-05-08 베르선 코포레이션 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201519352D0 (en) * 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2017107089A1 (fr) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. Modulateurs allostériques 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine
WO2018002760A1 (fr) * 2016-07-01 2018-01-04 Pfizer Inc. Dérivés de 5,7-dihydro-pyrrolo-pyridine pour le traitement de maladies neurologiques et neurodégénératives
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112843A1 (fr) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Modulateurs allostériques d'éther hétéroarylpipéridine du récepteur muscarinique de l'acétylcholine m4
WO2018112842A1 (fr) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Modulateurs allostériques d'éther hétéroarylpipéridine 6,6-fusionné du récepteur muscarinique de l'acétylcholine m4
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
EP3643703A4 (fr) 2017-06-21 2020-12-23 Daiichi Sankyo Co., Ltd. Inhibiteur de ep300/crebbp
WO2019000238A1 (fr) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. Modulateurs allostériques de 5-(pyridin-3-yl)oxazole du récepteur muscarinique m4 de l'acétylcholine
WO2019000237A1 (fr) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. Modulateurs allostériques de 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine
WO2019000236A1 (fr) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. Modulateurs allostériques de 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine
JP7166331B2 (ja) * 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
WO2019126559A1 (fr) 2017-12-20 2019-06-27 Vanderbilt University Antagonistes du récepteur muscarinique de l'acétylcholine m4
DK3768669T3 (da) * 2018-03-23 2023-04-24 Pfizer Piperazinazaspiroderivater
GB201810245D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
JP7349570B2 (ja) * 2019-10-09 2023-09-22 ノバルティス アーゲー Ｍ４作動薬としての２－アザスピロ［３．４］オクタン誘導体
AU2020364186B2 (en) * 2019-10-09 2023-11-30 Novartis Ag 5-oxa-2-azaspiro(3.4)octane derivatives as M4 agonists
US11912705B2 (en) * 2020-08-20 2024-02-27 The Corporation Of Mercer University Cathinone derivatives, pharmaceutical formulations, and methods
WO2023114224A1 (fr) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combinaison de modulateurs positifs du récepteur muscarinique et de modulateurs allostériques positifs de nmda
WO2024028458A2 (fr) 2022-08-04 2024-02-08 Heptares Therapeutics Limited Agonistes du récepteur muscarinique
WO2024059249A1 (fr) * 2022-09-16 2024-03-21 Cerevel Therapeutics, Llc Activateurs/modulateurs m4 et leurs utilisations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
AU2206699A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
JPWO2002085890A1 (ja) * 2001-04-20 2004-08-12 萬有製薬株式会社 ベンズイミダゾロン誘導体
EP1753429A1 (fr) * 2004-05-28 2007-02-21 Vertex Pharmaceuticals Incorporated Modulateurs de récepteurs muscariniques
WO2006105035A2 (fr) * 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Modulateurs muscariniques
CA2634456A1 (fr) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulateurs de recepteurs muscariniques
EP1988892A2 (fr) 2006-02-22 2008-11-12 Vertex Pharmaceuticals Incorporated Modulateurs des récepteurs muscariniques
NZ570497A (en) 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
EP1994027A2 (fr) * 2006-03-03 2008-11-26 Novartis AG Composes de n-formyle hydroxylamine
GB0706188D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2012020813A1 (fr) * 2010-08-10 2012-02-16 大日本住友製薬株式会社 Dérivé de pyrrolidine cyclique condensée
US9187451B2 (en) * 2011-11-18 2015-11-17 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
CN104640851B (zh) * 2012-09-18 2017-05-31 赫普泰雅治疗有限公司 作为毒蕈碱的m1受体激动剂的二环氮杂化合物
JP6373973B2 (ja) 2013-04-30 2018-08-15 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｚｅｓｔｅホモログ２エンハンサー阻害剤
CA2938169C (fr) * 2014-02-06 2022-03-15 Heptares Therapeutics Limited Composes d'aza bicyclique comme agonistes de recepteur muscarinique m1
EA033866B1 (ru) 2014-02-06 2019-12-03 Рибосайенс Ллк 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
EA035848B1 (ru) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
PE20170697A1 (es) 2014-09-19 2017-06-24 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1
LT3447050T (lt) 2014-09-19 2020-05-11 Forma Therapeutics, Inc. Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitrato dehidrogenazės inhibitoriai
US9938260B2 (en) 2014-09-19 2018-04-10 Glaxosmithkline Intellectual Property Development Limited Soluble guanylate cyclase activators and their use

Also Published As

Publication number Publication date
PL3102568T3 (pl) 2019-01-31
HRP20181499T1 (hr) 2018-11-30
JP6774513B2 (ja) 2020-10-28
KR102352388B1 (ko) 2022-01-17
AU2015213900A1 (en) 2016-08-11
PH12016501570A1 (en) 2016-10-03
UA122121C2 (uk) 2020-09-25
ES2688548T3 (es) 2018-11-05
EP3102568B1 (fr) 2018-06-27
US20200325118A1 (en) 2020-10-15
JP2017505323A (ja) 2017-02-16
JP2023073504A (ja) 2023-05-25
WO2015118342A8 (fr) 2016-06-30
CA2938169C (fr) 2022-03-15
DK3102568T3 (en) 2018-10-08
CL2016001983A1 (es) 2017-06-23
MX371529B (es) 2020-01-31
MX2020001236A (es) 2022-06-30
US10196380B2 (en) 2019-02-05
LT3102568T (lt) 2018-11-12
US9926297B2 (en) 2018-03-27
MX2016010322A (es) 2017-04-27
PH12016501570B1 (en) 2016-10-03
US10689368B2 (en) 2020-06-23
CN109851610A (zh) 2019-06-07
RU2685230C2 (ru) 2019-04-17
US10385039B2 (en) 2019-08-20
CN106458986B (zh) 2019-01-04
US10961225B2 (en) 2021-03-30
CN109851610B (zh) 2021-09-21
EP3102568A1 (fr) 2016-12-14
IL247117A0 (en) 2016-09-29
JP2019077725A (ja) 2019-05-23
BR112016017979B1 (pt) 2022-08-02
EP3406609A1 (fr) 2018-11-28
NZ723103A (en) 2022-09-30
JP2021006571A (ja) 2021-01-21
AU2015213900B2 (en) 2018-12-13
JP2023087045A (ja) 2023-06-22
AU2019201579B2 (en) 2020-08-27
SA516371614B1 (ar) 2019-10-30
CY1120834T1 (el) 2019-12-11
US20190112294A1 (en) 2019-04-18
AU2020277225A1 (en) 2020-12-24
US9670183B2 (en) 2017-06-06
CA2938169A1 (fr) 2015-08-13
PT3102568T (pt) 2018-10-24
US20190337925A1 (en) 2019-11-07
SI3102568T1 (sl) 2018-11-30
US20170015650A1 (en) 2017-01-19
WO2015118342A1 (fr) 2015-08-13
RU2016133684A3 (fr) 2018-08-31
CN106458986A (zh) 2017-02-22
US20180179184A1 (en) 2018-06-28
US20170240530A1 (en) 2017-08-24
AU2019201579A1 (en) 2019-03-28
BR112016017979A2 (fr) 2017-08-08
JP2023087046A (ja) 2023-06-22
SG11201606269WA (en) 2016-09-29
RS57843B1 (sr) 2018-12-31
JP6479029B2 (ja) 2019-03-06
RU2016133684A (ru) 2018-03-14
IL247117B (en) 2021-03-25
KR20160129014A (ko) 2016-11-08

Similar Documents

Publication Publication Date Title
HK1231473A1 (zh) 作為毒蕈碱 和/或 受體激動劑的雙環氮雜化合物
HK1248218A1 (zh) 作為毒蕈碱m1受體和/或m4受體的激動劑的螺環化合物
HK1231382A1 (zh) 毒蕈碱受體激動劑
HK1253036A1 (zh) 作為毒蕈碱m1和/或m4受體的激動劑的肟化合物
HK1245249A1 (zh) 二環喹唑啉酮衍生物
EP3193855A4 (fr) Composés bicycliques
IL254476A0 (en) Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists
GB2540892B (en) Pyrrolobenzodiazepine compounds
ZA201701210B (en) Substituted bicyclic compounds
IL251413A0 (en) Composition of injectable buprenorphine
HK1252614A1 (zh) 二環化合物
GB2530559B (en) Mixing bowl
EP3135674A4 (fr) Nouveau composé hétérocyclique bicyclique ou tricyclique
EP3131883A4 (fr) Antagonistes de 5-ht2b
ZA201607353B (en) Bicyclic derivatives and pharmaceutical composition including the same
GB201502644D0 (en) Bicyclic aza compounds as muscarinic m1 receptor agonists
GB201402210D0 (en) Mixing bowl